Brazil · Delayed Price · Currency is BRL AbbVie Statistics
Total Valuation
AbbVie has a market cap or net worth of BRL 1.92 trillion. The enterprise value is 2.25 trillion.
| Market Cap | 1.92T |
| Enterprise Value | 2.25T |
Important Dates
The next estimated earnings date is Friday, April 24, 2026.
| Earnings Date | Apr 24, 2026 |
| Ex-Dividend Date | Jan 15, 2026 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.11% |
| Owned by Insiders (%) | 0.07% |
| Owned by Institutions (%) | 75.32% |
| Float | 1.77B |
Valuation Ratios
The trailing PE ratio is 83.12 and the forward PE ratio is 14.07.
| PE Ratio | 83.12 |
| Forward PE | 14.07 |
| PS Ratio | 5.69 |
| PB Ratio | -107.78 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 19.53 |
| P/OCF Ratio | 18.28 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.36, with an EV/FCF ratio of 22.93.
| EV / Earnings | 97.60 |
| EV / Sales | 6.96 |
| EV / EBITDA | 14.36 |
| EV / EBIT | 20.16 |
| EV / FCF | 22.93 |
Financial Position
The company has a current ratio of 0.67
| Current Ratio | 0.67 |
| Quick Ratio | 0.41 |
| Debt / Equity | n/a |
| Debt / EBITDA | 2.31 |
| Debt / FCF | 3.84 |
| Interest Coverage | 7.30 |
Financial Efficiency
Return on equity (ROE) is 6,225.00% and return on invested capital (ROIC) is 22.49%.
| Return on Equity (ROE) | 6,225.00% |
| Return on Assets (ROA) | 9.81% |
| Return on Invested Capital (ROIC) | 22.49% |
| Return on Capital Employed (ROCE) | 23.29% |
| Weighted Average Cost of Capital (WACC) | 5.53% |
| Revenue Per Employee | 5.91M |
| Profits Per Employee | 404,500 |
| Employee Count | 57,000 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 3.80 |
Taxes
In the past 12 months, AbbVie has paid 13.02 billion in taxes.
| Income Tax | 13.02B |
| Effective Tax Rate | 35.83% |
Stock Price Statistics
The stock price has decreased by -11.92% in the last 52 weeks. The beta is 0.33, so AbbVie's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | -11.92% |
| 50-Day Moving Average | 73.03 |
| 200-Day Moving Average | 72.15 |
| Relative Strength Index (RSI) | 31.74 |
| Average Volume (20 Days) | 1,198 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.12 |
Income Statement
In the last 12 months, AbbVie had revenue of BRL 336.87 billion and earned 23.06 billion in profits. Earnings per share was 13.00.
| Revenue | 336.87B |
| Gross Profit | 241.27B |
| Operating Income | 116.30B |
| Pretax Income | 36.34B |
| Net Income | 23.06B |
| EBITDA | 161.13B |
| EBIT | 116.30B |
| Earnings Per Share (EPS) | 13.00 |
Balance Sheet
The company has 28.96 billion in cash and 376.75 billion in debt, with a net cash position of -347.79 billion.
| Cash & Cash Equivalents | 28.96B |
| Total Debt | 376.75B |
| Net Cash | -347.79B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -17.78B |
| Book Value Per Share | -10.19 |
| Working Capital | -78.36B |
Cash Flow
In the last 12 months, operating cash flow was 104.82 billion and capital expenditures -6.69 billion, giving a free cash flow of 98.13 billion.
| Operating Cash Flow | 104.82B |
| Capital Expenditures | -6.69B |
| Depreciation & Amortization | 43.25B |
| Net Borrowing | -1.62B |
| Free Cash Flow | 98.13B |
| FCF Per Share | n/a |
Margins
Gross margin is 71.62%, with operating and profit margins of 34.52% and 6.91%.
| Gross Margin | 71.62% |
| Operating Margin | 34.52% |
| Pretax Margin | 10.79% |
| Profit Margin | 6.91% |
| EBITDA Margin | 47.83% |
| EBIT Margin | 34.52% |
| FCF Margin | 29.13% |
Dividends & Yields
This stock pays an annual dividend of 1.53, which amounts to a dividend yield of 2.28%.
| Dividend Per Share | 1.53 |
| Dividend Yield | 2.28% |
| Dividend Growth (YoY) | 4.13% |
| Years of Dividend Growth | 6 |
| Payout Ratio | 275.84% |
| Buyback Yield | n/a |
| Shareholder Yield | 2.28% |
| Earnings Yield | 1.20% |
| FCF Yield | 5.12% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 21, 2022. It was a forward split with a ratio of 16.
| Last Split Date | Nov 21, 2022 |
| Split Type | Forward |
| Split Ratio | 16 |
Scores
AbbVie has an Altman Z-Score of 2.26 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.26 |
| Piotroski F-Score | 8 |